Former Thomson Reuters Executive to Guide Strategic Growth of Global
Life Science Intelligence Services Leader
LONDON AND BOSTON, Sept. 12, 2012 /CNW/ - EvaluatePharma®, the premier source for life science sector analysis and consensus
forecasts, has appointed Alexander Karle as Chief Operating Officer.
Karle's experience in formulating customer-centric growth strategies
and leading them to successful implementation will be instrumental in
driving EvaluatePharma's continued expansion within key industry
sectors and geographic markets.
Prior to joining EvaluatePharma, Karle served as Vice President of
Strategy and Development for global intelligence firm Thomson Reuters.
There, he served on the executive leadership team and was responsible
for defining and leading the corporate growth strategy for Thomson
Reuters' intellectual property and science division, an $800M+
information and services business. Karle also led the restructuring of
Thomson Reuters' pharmaceutical benchmarking business, CMR
International, where he set strategy and defined new services to
integrate with Thomson Reuters' life sciences business. Karle began his
professional career as a Senior Associate at Booz Allen & Hamilton.
Karle holds a Bachelor of Arts in business, economics and law from the
European Business Programme in Münster, Germany and Hull, United
Kingdom as well as a Master of Business Administration from Yale
University's School of Management.
"Alexander brings a breadth of experience in driving corporate
development for global intelligence firms within the life sciences. His
expertise in driving successful operational growth for Thomson Reuters'
science and healthcare businesses will be incredibly relevant," said
Dr. Jonathan de Pass, EvaluatePharma CEO. "We are thrilled to welcome
someone of his caliber to our executive leadership team."
Since 1996, EvaluatePharma has been the premier source for life science
sector analysis, delivering exclusive, trusted commercial insight into
industry performance through its proprietary platform. EvaluatePharma
is staffed by a team of over 85 dedicated healthcare analysts employing
rigorous methodologies to deliver the most-up-to-date commercial
performance data available. An award winning editorial team of
journalists writing under the EP Vantage name support EvaluatePharma's analysis. The EvaluatePharma services
enable the life science community to make sound business decisions
about value and opportunity. For more information please visit http://www.EvaluatePharma.com.
SOURCE: EvaluatePharma Ltd
For further information: